Search
Meet Ruben Escobar, an MSK security guard who values his family members, friends, and colleagues who have helped him get through life’s pivots and challenges.
Updated results of a clinical trial that launched in 2007 were presented today by Ethan Basch, MD, of Memorial Sloan Kettering Cancer Center (MSK) and UNC Lineberger Comprehensive Cancer Center, at the annual meeting of the American Society of Clinical Oncology. Data showed that systematic symptom monitoring during outpatient chemotherapy using web-based patient-reported outcomes (PROs) improved overall survival.
Hartford Healthcare Cancer Institute becomes first health system in the nation designated as MSK Care Partner.
Learn how GSK graduate Dr. Ellen Horste’s time investigating fundamental biological questions prepared her for a career in the emerging field of gene therapy.
Learn more about five essential strategies for coping with the fear of cancer, from MSK psychiatrist Dr. Monique James.
Learn the differences between physician assistants and nurse practitioners and the important roles they play at Memorial Sloan Kettering.
When an immune cell faces a foe, it has more than chemical weapons at its disposal.
Learn about how the immunotherapies ipilimumab (Yervoy®) and nivolumab (Opdivo®) could provide a new option for patients with metastatic renal cell carcinoma.
Two studies on multiple myeloma provide new information about diagnosing and treating this blood cancer.
Sloan Kettering Institute investigators have found that a subpopulation of cells within a type of sarcoma called malignant peripheral nerve sheath tumor appear to be similar to a type of neural stem cells.